


Restoring life after organ failure.

eGenesis is a biotechnology company committed to using its multiplex gene editing and genome engineering platform to revolutionize the treatment of organ failure. We have built a porcine genome engineering platform using advanced gene editing to create donors compatible for human transplantation. Our approach focuses on three classes of genetic edits to address retroviral risk and improve immunologic as well as molecular compatibility with human recipients.



Transformational Progress Since Inception

2017 → 2025

- First successful production of donors with retroviral inactivation (Science, 2017)
- Produced first transgenic donor carrying 3 classes of edits addressing historical challenges in cross-species transplantation (2021)
- Published landmark preclinical study (Nature, 2023) showing most extensive xenotransplant data and durable recipient survival
- Supplied EGEN-2784 kidney for world's first pig to living human kidney transplant (March 2024)
- Achieved record of 271 days dialysis independence for second patient to receive EGEN-2784 kidney (2025)

Upcoming Portfolio Milestones

2026

Next 18 Months

- KIDNEY EGEN-2784 Clinical**
Initiation of 33-patient Phase 1/2/3 study of patients with kidney failure waitlisted for transplant. Demonstration of early clinical proof of concept (6 months dialysis independence)
- LIVER EGEN-5784 ELC Clinical**
Completion of 20-patient Phase 1 study and demonstration of clinical proof of concept in ACLF patients.
- HEART EGEN-4467 Preclinical**
Completion of additional nonclinical studies to support IND filing and clarification of regulatory pathway for initial indication.

ORIGIN	Harvard University, 2016
DEVELOPMENT STAGE	Clinical
HEADQUARTERS	Cambridge, MA
CAPITAL RAISED	\$463M
LAST FINANCING	\$200M, 3Q24

Partnership Opportunities

- Pursuing regional and geographically focused partnerships
- Partnering with Immunology & Inflammation innovators, particularly in the areas of B- and T-cell suppression and complement inhibition

Team

Experienced team of scientific, technical, and operational leaders with commitment to revolutionizing the treatment of organ failure

Mike Curtis, Ph.D. PRESIDENT & CHIEF EXECUTIVE OFFICER

Jennifer Bergheiser CHIEF BUSINESS OFFICER

Jay Barth, M.D. CHIEF MEDICAL OFFICER

Susan Low, Ph.D. HEAD OF DEVELOPMENT

Wenning Qin, Ph.D. SVP, INNOVATION

Elizabeth Roberts CHIEF PEOPLE OFFICER

Learn more egenesisbio.com

Get in touch investors@egenesisbio.com